Monographie - Irinotecan - Stabilis 4.0

Poslední aktualizace :
08/05/2024

Rakovina drog

Irinotecan

Injekce

Stabilita roztoků

Stabilita směsí

Faktory ovlivňující stabilitu

Kompatibilita

Způsoby aplikace

Odkazy

Pdf

Chemický vzorec

Obchodní název

Obchodní název

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Asinib	Mexiko
Axinotecan	NÏmecko
Campto	äpanÏlsko, Belgie, Chorvatsko, Dánsko, Finsko, Francie, Indie, Írán, Irsko, Itálie, Japonsko, Jihoafrická republika, Lucembursko, Malajsie, MaÔarsko, Maroko, Nizozemsko, Norsko, Polsko, Portugalsko, Rakousko, Spojené arabské emiráty, Švédsko, Švýcarsko, Thajsko, Tunisko, Turecko, Velká Británie, ÿecko
Camptosar	BrazÌlie, Kanada, USA
Irinoliquid	Rakousko
Irnocam	BrazÌlie

Odkazy

Injekce

Odkazy : Irinotecan

	Typ	Uveřejnění
1423	Noviny	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1617	Noviny	Li WY, Koda RT. Stability of irinotecan hydrochloride in aqueous solutions. Am J Health-Syst Pharm 2002 ; 59: 539-544.
1662	Noviny	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1918	Noviny	Dodds HM, Craik DJ, Rivory LP. Photodegradation of irinotecan (CPT-11) in aqueous solutions : identification of fluorescent products and influence of solution composition. J Pharm Sci 1997 ; 86, 12: 1410-1416.
1920	Noviny	Akimoto K, Kaway A, Ohya K et al. Photodegradation reactions of CPT-11, a derivative of campothecion, part i: chemical structure of main degradation products in aqueous solution. Drug Stability 1996 ; 1: 118-122.
1921	Noviny	Akimoto K, Kawai A, Ohya K. Photodegradation reactions of CPT-11, a derivative of campothecion, part ii: photodegradation behaviour of CPT-11 in aqueous solution. Drug Stability 1996 ; 1; 141-146.
1953	Noviny	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1976	Noviny	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241.
2027	Noviny	Walker SE, Shirley L, Puodziunas A. Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. Can J Hosp Pharm 2005 ; 58: 212-222.
2143	Noviny	Dodds HM, Robert J, Rivory LP. The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry. J Pharm Biomed Anal 1998 ; 17: 785-792.
2168	Noviny	Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2241	Noviny	Thiesen J, Krämer I. Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags. J Oncol Pharm Practice 2000 ; 6, 3: 115-121.
2340	Noviny	Walker S.E, Law S, Puodziunas A. Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers Can J Hosp Pharm 2005 ; 58, 4: 212-222.
2671	Noviny	Kaiser J, Thiesen J, Krämer I. Stability of irinotecan-loaded eluting beads (DC Bead) used for transarterial chemoembolization. J Oncol Pharm Practice 2010 ; 16: 53-61.
3129	Laboratoř	Irinotécan (Campto®) – Résumé des caractéristiques du produits Pfizer 2008
3369	Laboratoř	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3670	Noviny	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3873	Noviny	Tan X, Hu J. Incompatibility between irinotecan and fluorouracil injections Am J Health-Syst Pharm 2016 ; 73:755.

Mentions Légales